How to choose a strategic partner in sterile manufacturing - Diatheva

Author: Maria Elena Laguardia

The manufacturing of sterile products (biological drugs, injectables, medical devices) represents the most complex and critical frontier of the life sciences. Contamination risks are not only operational, but can fatally compromise patient safety. For this reason, the choice of a CDMO (Contract Development and Manufacturing Organization) goes beyond simple outsourcing: it is a strategic decision that requires a due diligence analysis based on excellence criteria.

A strategic partner must offer an end-to-end service, capable of supporting the client from R&D (Research and Development) to final production, in strict compliance with Good Manufacturing Practices (GMP).

Sterile manufacturing and GMP compliance: key requirements for selecting a CDMO partner

The reliability of a CDMO is built on an unassailable regulatory and technological foundation.

The Evolution of contamination control: GMPs are the system that ensures consistent product quality. In Europe, Annex 1 of the EU-GMP regulations established a fundamental shift, from an emphasis on “good practices” to a systemic and proactive approach. This translates into the widespread adoption of a Contamination Control Strategy (CCS) and rigorous Quality Risk Management (QRM) throughout the entire product lifecycle. A partner must demonstrate a robust Quality Management System (QMS), not limited to minimum requirements.
Cleanrooms and pressure: Sterile manufacturing areas are classified into four grades (A, B, C, D), correlated with the ISO 14644-1 classification. The most critical areas (Grade A, ISO 5) are dedicated to aseptic filling and must operate under positive pressure (pressure differential of 10–15 Pa) to prevent the ingress of contaminated air from less clean areas.

For an accurate evaluation, attention must be focused on the following interconnected criteria:

Selection criterion: Description of Added Value
Regulatory compliance: Authorizations from agencies such as AIFA, EMA and FDA. Clean inspection history and assurance of batch traceability.
Scientific expertise: Experience and qualifications of the team (e.g. percentage of PhDs). The ability to conduct in-house R&D is the indicator of an innovation partner.
Operational flexibility: Scalability to support the project from the preclinical phase (milligram-scale batches) to the clinical phase (multi-gram), reducing technology transfers.
Quality and control: Robustness of the QMS, rigorous process and test validation procedures, and availability of a state-of-the-art QC laboratory.
Financial stability: Stability of the company and its parent group, essential for operational continuity and to ensure a long-term partnership.

Diatheva as a strategic Biotech CDMO for sterile manufacturing

Diatheva demonstrates strong alignment with these criteria, positioning itself as a strategic partner in the biological sector:

Regulatory compliance and authorizations: Diatheva operates under GMP conditions and has been authorized by AIFA for biological APIs since 2006. In a key expansion, it obtained authorization for sterile finished medicinal products in 2023. All activities are fully aligned.
Expertise and R&D: Founded as a spin-off of the University of Urbino, Diatheva has a strong research-driven foundation supported by a team with over 70% PhDs. This deep scientific expertise makes it an innovation partner, not merely an executor.
Flexibility and end-to-end services: It offers a complete portfolio of end-to-end CDMO services, including cell line development, Master and Working Cell Bank production, and microbial fermentation up to 300 L. The ability to produce batches of any size ensures operational flexibility and an economic advantage for start-ups and large companies.
Financial stability: The acquisition in 2012 by SOL Group, a consolidated industrial group, ensures financial stability and the resources necessary for future investments.

Conclusions

The selection of a CDMO for sterile manufacturing is a critical decision-making process. Diatheva’s end-to-end approach and the integration of R&D and GMP production phases into a single workflow represent a competitive advantage. Combined with certified infrastructure, a strong scientific base and financial stability, Diatheva positions itself as a true strategic partner whose objective is to ensure project success and patient safety.

Maria Elena Laguardia is the Site Manager and Qualified Person at Diatheva. With a PhD in Biochemical and Pharmacological Methodologies, she oversees the site’s operations and ensures compliance with regulatory standards. She plays a crucial role in product development and maintaining operational excellence within the Biotech CDMO division.

References:

DIATHEVA – PharmaSource, https://pharmasource.global/directory/diatheva/
GMP vs ISO: What’s the Difference? – Bachem, https://www.bachem.com/articles/blog/gmp-vs-iso-whats-the-difference/
Guidelines for inspections of manufacturers of medicinal products for advanced therapies and somatic cell therapy, https://www.aifa.gov.it/sites/default/files/linea_guida_produttori_medicinali_rev1.pdf
EU GMP Annex 1: Manufacture of Sterile Medicinal Products – ECA Academy, https://www.gmp-compliance.org/guidelines/gmp-guideline/eu-gmp-annex-1-manufacture-of-sterile-medicinal-products
Annex 1: Manufacture of Sterile Products – Document map, Section Number, General overview, 1. Scope, Includes additional areas (other) – Public Health – European Commission, https://health.ec.europa.eu/document/download/6eaee230-0dde-4bd2-b4b8-4f248be26d13_en
GMP Annex 1 Implementation | PDA – Parenteral Drug Association, https://www.pda.org/pda-letter-portal/home/full-article/gmp-annex-1-implementation
Article 1 – Official Gazette of the Italian Republic, https://www.gazzettaufficiale.it/atto/serie_generale/caricaArticolo?art.progressivo=0&art.idArticolo=1&art.versione=1&art.codiceRedazionale=094A4190&art.dataPubblicazioneGazzetta=1994-06-28&art.idGruppo=3&art.idSottoArticolo1=10&art.idSottoArticolo=1&art.flagTipoArticolo=1
GMP Cleanroom Classifications: Grade A, B, C and D, https://gmpinsiders.com/gmp-cleanroom-classifications/
Cleanroom classes: ISO 14644 and GMP in focus – item – Blog, https://blog.item24.com/it/ingegneria-meccanica-e-impiantistica/classi-per-camere-bianche-iso-14644-e-gmp-in-primo-piano/
GMP EU Cleanroom Classifications A, B, C, D – High-Tech Conversions, https://high-techconversions.com/gmp-eu-cleanroom-classifications-a-b-c-d/
GMP: ANNEX 1 – MANUFACTURE OF STERILE MEDICINAL PRODUCTS – AIFA, https://www.aifa.gov.it/sites/default/files/Stoppa2.pdf
FAQs: Medical Device Manufacturing Certifications | Remington, https://remmed.com/medical-device-certification/
ISO Certifications for Medical Devices: Requirements and Benefits – Pacific Certifications, https://blog.pacificcert.com/iso-certifications-for-medical-devices-requirements-and-benefits/
Current Good Manufacturing Practice (CGMP) Regulations – FDA, https://www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-regulations
Biotech Companies in Nigeria – Coresignal, https://coresignal.com/discover/biotech/nigeria/